Search research articles
Contact Us
Filters
Showing results (1-10 of 22) with videos related to
Page
of 3
Sort By:
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
March 11, 2015
Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits
Jeffrey W Kiel, Casey C Kopczynski
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
December 6, 2013
Emerging trabecular outflow drugs
Casey C Kopczynski, David L Epstein
Ophthalmology and Therapy
|
November 27, 2020
A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma
James H Peace, Hayley J McKee, Casey C Kopczynski
Ophthalmology
|
October 2, 2014
Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure
Jason Bacharach, Harvey B Dubiner, Brian Levy, et al.
The British Journal of Ophthalmology
|
July 26, 2015
Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension
Richard A Lewis, Brian Levy, Nancy Ramirez, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
February 23, 2018
The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
Arash Kazemi, Jay W McLaren, Casey C Kopczynski, et al.
Frontiers in Ophthalmology
|
July 10, 2024
Effects of Netarsudil-Family Rho Kinase Inhibitors on Human Trabecular Meshwork Cell Contractility and Actin Remodeling Using a Bioengineered ECM Hydrogel
Tyler Bagué, Ayushi Singh, Rajanya Ghosh, et al.
Advances in Therapy
|
March 14, 2020
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
Sanjay Asrani, Jason Bacharach, Edward Holland, et al.
Advances in Therapy
|
August 21, 2023
Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET)
Makoto Araie, Kazuhisa Sugiyama, Kenji Aso, et al.
American Journal of Ophthalmology
|
June 24, 2019
Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial
Sanjay Asrani, Alan L Robin, Janet B Serle, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 22) with videos related to
Sort By:
Page
of 3
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
March 11, 2015
Effect of AR-13324 on episcleral venous pressure in Dutch belted rabbits
Jeffrey W Kiel, Casey C Kopczynski
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
December 6, 2013
Emerging trabecular outflow drugs
Casey C Kopczynski, David L Epstein
Ophthalmology and Therapy
|
November 27, 2020
A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma
James H Peace, Hayley J McKee, Casey C Kopczynski
Ophthalmology
|
October 2, 2014
Double-masked, randomized, dose-response study of AR-13324 versus latanoprost in patients with elevated intraocular pressure
Jason Bacharach, Harvey B Dubiner, Brian Levy, et al.
The British Journal of Ophthalmology
|
July 26, 2015
Fixed-dose combination of AR-13324 and latanoprost: a double-masked, 28-day, randomised, controlled study in patients with open-angle glaucoma or ocular hypertension
Richard A Lewis, Brian Levy, Nancy Ramirez, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics
|
February 23, 2018
The Effects of Netarsudil Ophthalmic Solution on Aqueous Humor Dynamics in a Randomized Study in Humans
Arash Kazemi, Jay W McLaren, Casey C Kopczynski, et al.
Frontiers in Ophthalmology
|
July 10, 2024
Effects of Netarsudil-Family Rho Kinase Inhibitors on Human Trabecular Meshwork Cell Contractility and Actin Remodeling Using a Bioengineered ECM Hydrogel
Tyler Bagué, Ayushi Singh, Rajanya Ghosh, et al.
Advances in Therapy
|
March 14, 2020
Fixed-Dose Combination of Netarsudil and Latanoprost in Ocular Hypertension and Open-Angle Glaucoma: Pooled Efficacy/Safety Analysis of Phase 3 MERCURY-1 and -2
Sanjay Asrani, Jason Bacharach, Edward Holland, et al.
Advances in Therapy
|
August 21, 2023
Phase 3 Clinical Trial Comparing the Safety and Efficacy of Netarsudil to Ripasudil in Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: Japan Rho Kinase Elevated Intraocular Pressure Treatment Trial (J-ROCKET)
Makoto Araie, Kazuhisa Sugiyama, Kenji Aso, et al.
American Journal of Ophthalmology
|
June 24, 2019
Netarsudil/Latanoprost Fixed-Dose Combination for Elevated Intraocular Pressure: Three-Month Data from a Randomized Phase 3 Trial
Sanjay Asrani, Alan L Robin, Janet B Serle, et al.
Page
of 3